Patients with MYC+/BCL2+ coexpression were more often of older age (P = 0.0016) and more often had advanced disease stage (P < 0.0001), extranodal involvement (P = 0.0026), large tumor size (P = 0.03), International Prognostic Index score > 2 (P < 0.0001), low complete response rate (P = 0.0071), and high Ki-67 (P = 0.0002), and the lymphoma was more often of ABC subtype (P = 0.0079). The gene discussed is BCL2; the disease is lymphoma.